Lyme Disease and Mycotoxicosis: How to Differentiate Between the Two

The health effects of Lyme disease and of molds and their mycotoxins frequently present in a similar manner, creating a significant diagnostic challenge for clinicians. Patients with either disorder — or both — share an extensive list of overlapping complaints including chronic fatigue, muscle and joint pain, memory disturbance, anxiety, depression, headaches, seizures, tremors, hair loss, heart palpitations, nausea, and chemical sensitivities. These symptoms are also frequently mistaken for multiple sclerosis, fibromyalgia, chronic fatigue syndrome, systemic lupus, Guillain-Barré syndrome, ALS, rheumatoid arthritis, and thyroiditis. This editorial reviews the clinical presentation, diagnostic pathways, and laboratory methodologies for both Lyme disease and mycotoxicosis, emphasizing the critical importance of accurate differentiation. For Lyme disease, the multi-peptide ELISA (MPE) is presented as more sensitive than Western Blot, capable of detecting antibodies to multiple Borrelia species. For mycotoxin exposure, blood serum antibody testing for IgG and IgE is established as the most accurate methodology, with 20 years of validated clinical use. The paper addresses the limitations of urine mycotoxin testing, noting that mycotoxins are found in the urine of healthy people due to normal dietary intake, and that 99.8% of ochratoxin binds to albumin in the blood, making urinary elimination negligible. The author presents clinical experience demonstrating that patients can have both conditions simultaneously, and that patients treated for years for Lyme disease without improvement may in fact have undiagnosed mycotoxicosis. The central thesis is that accurate diagnosis — achieved by combining clinical findings with the most sensitive laboratory methods available — is essential to identifying the correct treatment and achieving patient recovery.